−0.31USD
−20.94 MUSD
70.65 M
About Oncolytics Biotech Inc.
Sector
Industry
CEO
Matthew C. Coffey
Website
Headquarters
Calgary
Founded
1998
ISIN
CA6823108759
FIGI
BBG000DVS826
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Once buyDidnt break to the downside, start of a new bullish trend, going for a second Elliot wave, bullish market structure, reaction at the support line
ONCY: Daily VCPSetup: RocketBase
VCP: 9W 38/4 4T
RS: 89
The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 repre
ONCY: Bullish Pennant (51%)Bullish Pennant (51%)
Pros:
Volume during post formation
Descending volume during triangle formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0
R/R ratio above 5
ATR ascending
250RSI above 50 and ascending
200MA ascending
Cona:
RS Flat
Target:
PT = 5.45$
Help how ever you can to keep
$ONCY initiated with a Buy at H.C. Wainwright -302.14% potentialOncolytics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio initiated coverage of Oncolytics Biotech with a Buy rating and $15 price target. The company is "on the cusp of demonstrating potential to upend the treatment paradigms of several cancers," Trucchio tells in
ONCY: Another risky biotech to considerLong term downtrend line broken. V shaped upswing with much increased volume. It has a well patented potential product that has great promise in assisting in treatment of difficult cancers. Like all small biotech companies there is often a lot of volatility and risk. I'm looking for a rise to 9-15.
ONCY - Long SetupCould flag again if it breaks above 3.66. Stop signal 3.19. Smaller position to offset stop risk. Target 4.23(acorn is already holding an active position in this)
ONC.CA: Descending TriangleDescending Triangle
Pros:
Descending Volume
R/R Ratio above 9
Descending ATR
200MA flat/ascending
PPS below 50MA
Cons:
250RSI still close to 50
PPS above 200MA
If confirmed
PT1 = 2,10
PT2 = 1,43
PT3 = 0,95
Bonus PT4 = 0,75
ONCY LONGMore information was necessary to form this decision. Time and patience. ONCY has stayed in the ascending channel well. I will buy here, but this is not financial advice.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ONCY is 1.04 USD — it has decreased by 3.70% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oncolytics Biotech Inc. stocks are traded under the ticker ONCY.
Oncolytics Biotech Inc. is going to release the next earnings report on May 3, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Oncolytics Biotech Inc. has a max estimate of 6.63 USD and a min estimate of 2.21 USD.
ONCY earnings for the last quarter are −0.10 USD whereas the estimation was −0.08 USD which accounts for −31.01% surprise. Estimated earnings for the next quarter are −0.11 USD. See more details about Oncolytics Biotech Inc. earnings.
Yes, you can track Oncolytics Biotech Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, ONCY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oncolytics Biotech Inc. stock right from TradingView charts — choose your broker and connect to your account.